Evidence map›Paper›PMID 23525330›Full record

ArticleMolecular pharmacology2013

State-dependent etomidate occupancy of its allosteric agonist sites measured in a cysteine-substituted GABAA receptor.

Deirdre S Stewart, Mayo Hotta, Rooma Desai, Stuart A Forman

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. GABAJournal, genetic engineering & biotechnology · 2021
    Review
  6. Article
  7. Article
  8. Comparison of αβδ and αβγ GABAPharmacological research · 2018
    Review
  9. Article
  10. Review
  11. A Single Amino Acid Residue at Transmembrane Domain 4 of theThe Journal of pharmacology and experimental therapeutics · 2017
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Deirdre S StewartDepartment of Anesthesia Critical Care & Pain Medicine, Beecher-Mallinckrodt Research Laboratories, and Department of Anesthesia Critical Care & Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.
Mayo Hotta
Rooma Desai
Stuart A Forman
Mallinckrodt (United States) · USHarvard University · USMassachusetts General Hospital · US

Funding

Synthetic Chemistry CoreP01GM058448 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KEITH W · 1999 to 2018
$33.6M
General Anesthetic Sites in GABA-A Receptor Subunit Interfacial PocketsR01GM089745 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI FORMAN, STUART A · 2010 to 2020
$3.8M
NIGMS NIH HHS GM089745NIGMS NIH HHS GM58448NIGMS NIH HHS P01 GM058448NIGMS NIH HHS R01 GM089745
6 · The paper itself

Abstract

A central axiom of ligand-receptor theory is that agonists bind more tightly to active than to inactive receptors. However, measuring agonist affinity in inactive receptors is confounded by concomitant activation. We identified a cysteine substituted mutant γ-aminobutyric acid type A (GABAA) receptor with unique characteristics allowing the determination of allosteric agonist site occupancy in both inactive and active receptors. Etomidate, the allosteric agonist, is an anesthetic that activates or modulates α1β2γ2L GABAA receptors via transmembrane sites near β2M286 residues in M3 domains. Voltage-clamp electrophysiology studies of α1β2M286Cγ2L receptors show that GABA is an efficacious agonist and that etomidate modulates GABA-activated activity, but direct etomidate agonism is absent. Quantitative analysis of mutant activity using an established Monod-Wyman-Changeux (MWC) allosteric model indicates that the intrinsic efficacy of etomidate, defined as its relative affinity for active versus inactive receptors, is lower than in wild-type receptors. Para-chloromercuribenzene sulfonate covalently modifies β2M286C side-chain sulfhydryls, irreversibly altering GABA-induced currents. Etomidate concentration dependently reduces the apparent rate of β2M286C-pCMBS bond formation, tracked electrophysiologically. High etomidate concentrations completely protect the β2M286C suflhydryl from covalent modification, suggesting close steric interactions. The 50% protective etomidate concentration (PC50) is 14 μM in inactive receptors and 1.1 to 2.2 μM during GABA-activation, experimentally demonstrating that activated receptors bind etomidate more avidly than do inactive receptors. The experimental PC50 values are remarkably close to, and therefore validate, MWC model predictions for etomidate dissociation constants in both inactive and active receptors. Our results support MWC models as valid frameworks for understanding the agonism, coagonism, and modulation of ligand-gated ion channels.

Indexed as

Allosteric SiteAnesthetics, GeneralAnimalsBinding SitesCysteineEtomidateFemaleGABA-A Receptor AgonistsHEK293 CellsHumansModels, MolecularMutationOocytesPatch-Clamp TechniquesReceptors, GABA-AXenopus laevisAnesthetics, GeneralCysteineEtomidateGABA-A Receptor AgonistsReceptors, GABA-A

Identifiers

PMID23525330
PMCPMC3657098
OpenAlexW2161329715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.